Nasdaq:US$20.17 (-0.79) | HKEX:HK$31.70 (-1.70) | AIM:£3.24 (-0.13)
上一篇文章   |   下一篇文章
公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-03-21

Chi-Med to host R&D Briefings on March 29 & 30, 2017

Press Release

London: Tuesday, March 21, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that it will host Research & Development (“R&D”) briefings in London and New York to provide an overview of the Company’s clinical pipeline of eight novel drug candidates.  The events for analysts and investors will take place in London on Wednesday, March 29, and in New York on Thursday, March 30, 2017.

Chi-Med is a China-based biopharmaceutical company focused on discovering and developing targeted therapies for oncology and immunological diseases for the global market.  The Company has 30 ongoing clinical trials with eight novel drug candidates, which are expected to report a steady flow of pivotal Phase III trial results from this year onwards.  Chi-Med’s first drug is targeted to launch next year in China.

The Chi-Med management team will outline the Company’s R&D strategy and discuss its drug candidate pipeline during the briefings.


Date: Wednesday, March 29, 2017 Thursday, March 30, 2017
City: London New York

9:15am Registration

9:30am-12:30pm Program Presentation

Lunch will be provided afterwards

8:00am Registration & Breakfast

8:30am-11:30am Program Presentation

Address: South Place Hotel, 3 South Place, London, EC2M 2AF W Hotel, 541 Lexington Ave, New York, NY 10022
Keynote Speaker: Dr Susan Galbraith, Vice President, AstraZeneca PLC (“AstraZeneca”)


The briefing on Wednesday, March 29, 2017 in London will begin with a keynote presentation from Dr Susan Galbraith, Vice President of Oncology Innovative Medicines and Early Development at AstraZeneca.

Mr Christian Hogg, Chief Executive Officer; Dr Weiguo Su, Executive Vice President and Chief Scientific Officer; Dr Zhenping Wu, Senior Vice President of Pharmaceutical Sciences; and Dr May Wang, Senior Vice President of Business Development & Strategic Alliances, will be presenting on Chi-Med’s research & development and partnering activities. Chi-Med currently has partnerships with AstraZeneca, Eli Lilly and Company and Nestlé Health Science S.A.

To register for the London briefing, please contact Dr Marine Perrier by telephone at +44 20 7282 1068 or by email at

To register for the New York briefing, please contact Matt Beck by telephone at +1 646 378 2933 or by email at

No new material trading or financial information will be disseminated at the meeting.  Following the meeting, the presentations will be made available at



Investor Enquiries

Christian Hogg, CEO
+852 2121 8200

U.K. and International Media Enquiries

Anthony Carlisle, Citigate Dewe Rogerson
+44 7973 611 888 (Mobile)

U.S. Based Media Enquiries

Brad Miles, BMC Communications
+1 (917) 570 7340 (Mobile)

Susan Duffy, BMC Communications
+1 (917) 499 8887 (Mobile)

Investor Relations

Matt Beck, The Trout Group
+1 (917) 415 1750 (Mobile)

David Dible, Citigate Dewe Rogerson
+44 7967 566 919 (Mobile)

Panmure Gordon (UK) Limited

Richard Gray / Andrew Potts
+44 (20) 7886 2500